131 related articles for article (PubMed ID: 38417442)
1. Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells.
Ding R; Yu X; Hu Z; Dong Y; Huang H; Zhang Y; Han Q; Ni ZY; Zhao R; Ye Y; Zou Q
Immunity; 2024 Mar; 57(3):528-540.e6. PubMed ID: 38417442
[TBL] [Abstract][Full Text] [Related]
2. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop.
Marangoni F; Zhakyp A; Corsini M; Geels SN; Carrizosa E; Thelen M; Mani V; Prüßmann JN; Warner RD; Ozga AJ; Di Pilato M; Othy S; Mempel TR
Cell; 2021 Jul; 184(15):3998-4015.e19. PubMed ID: 34157302
[TBL] [Abstract][Full Text] [Related]
3. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
[TBL] [Abstract][Full Text] [Related]
4. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
5. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer.
Matoba T; Imai M; Ohkura N; Kawakita D; Ijichi K; Toyama T; Morita A; Murakami S; Sakaguchi S; Yamazaki S
Int J Cancer; 2019 Jun; 144(11):2811-2822. PubMed ID: 30485427
[TBL] [Abstract][Full Text] [Related]
7. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid.
Watson MJ; Vignali PDA; Mullett SJ; Overacre-Delgoffe AE; Peralta RM; Grebinoski S; Menk AV; Rittenhouse NL; DePeaux K; Whetstone RD; Vignali DAA; Hand TW; Poholek AC; Morrison BM; Rothstein JD; Wendell SG; Delgoffe GM
Nature; 2021 Mar; 591(7851):645-651. PubMed ID: 33589820
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner.
Yuan XL; Chen L; Li MX; Dong P; Xue J; Wang J; Zhang TT; Wang XA; Zhang FM; Ge HL; Shen LS; Xu D
Clin Immunol; 2010 Mar; 134(3):277-88. PubMed ID: 19900843
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic characterization of ex vivo CD4+CD25highCD127low immune regulatory T cells in allergic asthma: pathogenesis relevance of their FoxP3, GITR, CTLA-4 and FAS expressions.
Pietruczuk M; Eusebio M; Kraszula L; Kupczyk M; Kuna P
J Biol Regul Homeost Agents; 2012; 26(4):627-39. PubMed ID: 23241113
[TBL] [Abstract][Full Text] [Related]
10. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.
Jie HB; Schuler PJ; Lee SC; Srivastava RM; Argiris A; Ferrone S; Whiteside TL; Ferris RL
Cancer Res; 2015 Jun; 75(11):2200-10. PubMed ID: 25832655
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
13. Human FOXP3 and tumour microenvironment.
Wang J; Gong R; Zhao C; Lei K; Sun X; Ren H
Immunology; 2023 Feb; 168(2):248-255. PubMed ID: 35689826
[TBL] [Abstract][Full Text] [Related]
14. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
15. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression.
Hiura T; Kagamu H; Miura S; Ishida A; Tanaka H; Tanaka J; Gejyo F; Yoshizawa H
J Immunol; 2005 Oct; 175(8):5058-66. PubMed ID: 16210609
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Regulatory T Cell-Related Markers (FOXP3, CTLA-4 and GITR) by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer.
Khalife E; Khodadadi A; Talaeizadeh A; Rahimian L; Nemati M; Jafarzadeh A
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3019-3025. PubMed ID: 30484986
[TBL] [Abstract][Full Text] [Related]
17. A deubiquitination module essential for T
Montauti E; Weinberg SE; Chu P; Chaudhuri S; Mani NL; Iyer R; Zhou Y; Zhang Y; Liu C; Xin C; Gregory S; Wei J; Zhang Y; Chen W; Sun Z; Yan M; Fang D
Sci Adv; 2022 Nov; 8(47):eabo4116. PubMed ID: 36427305
[TBL] [Abstract][Full Text] [Related]
18. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
19. Composition and plasticity of triple-negative breast carcinoma-infiltrating regulatory T cells.
Cai B; Ma P; Ding P; Sun DW; Bu Q; Zhang J
APMIS; 2020 Mar; 128(3):260-269. PubMed ID: 31811667
[TBL] [Abstract][Full Text] [Related]
20. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]